Transdiagnostic Treatment Personalization: Prioritizing Therapy Components to Capitalize on Strengths or Compensate for Weaknesses
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Anxiety Disorders
- Sponsor
- Shannon E. Sauer-Zavala
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Change in Clinical Severity
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The primary purpose of this study is to explore whether the efficiency of treatment for anxiety and depressive disorders can be increased using two discrete strategies: personalized skill ordering and 2) treatment discontinuation based on proximal indicators of improvements. The present study will specifically use treatment components drawn from an evidence-based psychological intervention, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP). This intervention has strong empirical support for patients presenting with anxiety, depressive, and related disorders and contains therapeutic skills that are common in psychological interventions (e.g., psychoeducation, mindfulness training, cognitive restructuring, countering emotional avoidance, increasing interoceptive tolerance). This study will determine if prioritizing the order of treatment modules to capitalize on patient strengths or compensate for weakensses increases treatmen efficacy. Additionally, it will also identify under what conditions briefer treatment modules may be appropriate.
Investigators
Shannon E. Sauer-Zavala
Assistant Professor
University of Kentucky
Eligibility Criteria
Inclusion Criteria
- •diagnosis of at least one emotional disorder
- •fluent in English
- •medication stability
Exclusion Criteria
- •concurrent therapy
- •psychological condition that would be better addressed by alternative treatments
- •have received more than 5 sessions of cognitive behavioral therapy in the past 5 years
Outcomes
Primary Outcomes
Change in Clinical Severity
Time Frame: 12 weeks (baseline, week 6 and week 12)
Clinical severity will be measured using the Diagnostic Interview for Anxiety, Mood, and Obsessive Compulsive and Related Neuropsychiatric Disorders (DIAMOND) dimensional clinician ratings. Scores range from 1-7; higher scores indicate greater severity.
Change in Anxiety Symptoms
Time Frame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
Anxiety symptoms will be measured using the Overall Anxiety Severity and Interference Scale (OASIS). This is a self-report measure in which scores range from 0-20; higher scores indicate more severe anxiety symptoms.
Change in Depressive Symptoms
Time Frame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
Depressive symptoms will be measured using the Overall Depression Severity and Interference Scale (ODSIS). This is a self-report measure in which scores range from 0-20; higher scores indicate more severe anxiety symptoms.
Change in Aversive Reactions to Emotions
Time Frame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
Aversive reactions to emotions will be measured using the distress aversion subscale of the Multidimensional Experiential Avoidance Questionnaire (MEAQ). This is a self-report measure in which scores range from 13-78; higher scores indicate greater negative reactions to emotional experiences.